S'abonner

Infections, hospitalisations, and deaths averted via a nationwide vaccination campaign using the Pfizer–BioNTech BNT162b2 mRNA COVID-19 vaccine in Israel: a retrospective surveillance study - 24/02/22

Doi : 10.1016/S1473-3099(21)00566-1 
Eric J Haas, MD a, c, *, John M McLaughlin, PhD d, *, Farid Khan, MPH d, Frederick J Angulo, PhD d, Emilia Anis, MD a, e, Marc Lipsitch, DPhil f, Shepherd R Singer, MD a, e, Gabriel Mircus, PhD g, Nati Brooks, MA h, Meir Smaja, BA h, Kaijie Pan, MS d, Jo Southern, PhD d, David L Swerdlow, MD d, Luis Jodar, PhD d, Yeheskel Levy, MD b, Sharon Alroy-Preis, MD a,
a Public Health Services, Jerusalem, Israel 
b Israel Ministry of Health, Jerusalem, Israel 
c Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheva, Israel 
d Pfizer, Collegeville, PA, USA 
e Hadassah Braun School of Public Health, Faculty of Medicine, Hebrew University, Jerusalem, Israel 
f Faculty of Medicine Harvard T H Chan School of Public Health, Boston, MA, USA 
g Pfizer Pharmaceuticals Israel, Herzliya, Israel 
h Information Technology Department, Israel Ministry of Health, Jerusalem, Israel 

* Correspondence to: Dr Sharon Alroy-Preis, Public Health Services, Israel Ministry of Health, Jerusalem 9101002, Israel Public Health Services Israel Ministry of Health Jerusalem 9101002 Israel

Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.

Connectez-vous pour en bénéficier!

Summary

Background

On Dec 20, 2020, Israel initiated a nationwide COVID-19 vaccination campaign for people aged 16 years and older and exclusively used the Pfizer–BioNTech BNT162b2 mRNA COVID-19 vaccine (tozinameran). We provide estimates of the number of SARS-CoV-2 infections and COVID-19-related admissions to hospital (ie, hospitalisations) and deaths averted by the nationwide vaccination campaign.

Methods

In this retrospective surveillance study, we used national surveillance data routinely collected by the Israeli Ministry of Health from the first 112 days (Dec 20, 2020, up to our data cutoff of April 10, 2021) of Israel’s vaccination campaign to estimate the averted burden of four outcomes: SARS-CoV-2 infections and COVID-19-related hospitalisations, severe or critical hospitalisations, and deaths. As part of the campaign, all individuals aged 16 years and older were eligible for inoculation with the BNT162b2 vaccine in a two-dose schedule 21 days apart. We estimated the direct effects of the immunisation programme for all susceptible individuals (ie, with no previous evidence of laboratory-confirmed SARS-CoV-2 infection) who were at least partly vaccinated (at least one dose and at least 14 days of follow-up after the first dose). We estimated the number of SARS-CoV-2 infection-related outcomes averted on the basis of cumulative daily, age-specific rate differences, comparing rates among unvaccinated individuals with those of at least partly vaccinated individuals for each of the four outcomes and the (age-specific) size of the susceptible population and proportion that was at least partly vaccinated.

Findings

We estimated that Israel’s vaccination campaign averted 158 665 (95% CI 144 640–172 690) SARS-CoV-2 infections, 24 597 (18 942–30 252) hospitalisations, 17 432 (12 770–22 094) severe or critical hospitalisations, and 5532 (3085–7982) deaths. 16 213 (65·9%) of 24 597 hospitalisations and 5035 (91·0%) of 5532 of deaths averted were estimated to be among those aged 65 years and older. We estimated 116 000 (73·1%) SARS-CoV-2 infections, 19 467 (79·1%) COVID-19-related hospitalisations, and 4351 (79%) deaths averted were accounted for by the fully vaccinated population.

Interpretation

Without the national vaccination campaign, Israel probably would have had triple the number of hospitalisations and deaths compared with what actually occurred during its largest wave of the pandemic to date, and the health-care system might have become overwhelmed. Indirect effects and long-term benefits of the programme, which could be substantial, were not included in these estimates and warrant future research.

Funding

Israel Ministry of Health and Pfizer.

Le texte complet de cet article est disponible en PDF.

Plan


© 2022  Elsevier Ltd. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 22 - N° 3

P. 357-366 - mars 2022 Retour au numéro
Article précédent Article précédent
  • Effectiveness of an inactivated virus-based SARS-CoV-2 vaccine, BBV152, in India: a test-negative, case-control study
  • Devashish Desai, Adil Rashid Khan, Manish Soneja, Ankit Mittal, Shivdas Naik, Parul Kodan, Ayan Mandal, Ganesh Tarachand Maher, Rohit Kumar, Ayush Agarwal, Naveen R Gowda, Vikas H, Parmeshwar Kumar, Shivam Pandey, R M Pandey, Arvind Kumar, Animesh Ray, Pankaj Jorwal, Neeraj Nischal, Aashish Choudhary, Megha Brijwal, Karan Madan, Rakesh Lodha, Sanjeev Sinha, Lalit Dar, Naveet Wig, Randeep Guleria
| Article suivant Article suivant
  • Supervised versus unsupervised primaquine radical cure for the treatment of falciparum and vivax malaria in Papua, Indonesia: a cluster-randomised, controlled, open-label superiority trial
  • Jeanne Rini Poespoprodjo, Faustina Helena Burdam, Freis Candrawati, Benedikt Ley, Niamh Meagher, Enny Kenangalem, Ratni Indrawanti, Leily Trianty, Kamala Thriemer, David J Price, Julie A Simpson, Ric N Price

Bienvenue sur EM-consulte, la référence des professionnels de santé.

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2025 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.